The drugs industry closed the day down 0.1%. ProPhase Labs Inc ( PRPH), Cardium Therapeutics Inc ( CXM), Galena Biopharma Inc ( RXII), and Senesco Technologies Inc ( SNT) were all winners today within the drugs industry with Pfizer Inc ( PFE) being today's featured drugs winner. Pfizer Inc rose 42 cents (2.4%) to $17.98 on average volume. Throughout the day, 47.8 million shares of Pfizer Inc exchanged hands as compared to its average daily volume of 53.2 million shares.

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. Pfizer Inc has a market cap of $138.5 billion and is part of the health care sector. The company has a P/E ratio of 16.6, above the average drugs industry P/E ratio of 16.4 and below the S&P 500 P/E ratio of 17.7. Shares are up 0.3% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, expanding profit margins and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, BioDelivery Sciences International Inc ( BDSI), Aoxing Pharmaceutical Company Inc ( AXN), NeurogesX Inc ( NGSX), and Marina Biotech Inc ( MRNA) were all losers within the drugs industry with Cytori Therapeutics Inc ( CYTX) being today's drugs industry Loser Spotlight stock.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux